Geneseeq's PanTRKare™ Receives Approval as Companion Diagnostic for VELMARTO®
On August 6, 2026, the NMPA granted significant approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit, recognizing it as the companion diagnostic tool for VELMARTO® (Eratrectinib). This approval is a crucial step in enhancing the clinical management of patients diagnosed with NTRK fusion-positive solid tumors, allowing for more precise treatment options.
The PanTRKare™ kit effectively addresses several testing challenges within the oncology landscape, specifically the pan-tumor distribution, low incidence rates, and the complex variation patterns of NTRK1/2/3 fusions. By enabling the accurate detection of NTRK fusion variants, this diagnostic tool significantly improves the way healthcare professionals can assess and treat patients with various cancer types.
In clinical settings, the efficacy of PanTRKare™ has been established through validation studies. Results demonstrate that patients with positive test results using PanTRKare™ have shown objective response rates that are in line with those recorded during the clinical trials for Eratrectinib. This consistency has been observed across both treatment-naïve and pre-treated populations, further endorsing the stability and reliability of the assay as a companion diagnostic instrument.
Eratrectinib itself has made waves in the pharmaceutical industry, marking a notable achievement as Nanjing's first innovative drug approval this year. By employing advanced cyclic structural optimization strategies, this next-generation TRK inhibitor exhibits a more potent and highly selective inhibition of TRK kinases. Such innovations effectively address the structural impediments and drug-resistance challenges that hindered the first-generation TRK inhibitors. The pivotal VC004-101 clinical trial showcases Eratrectinib's impressive clinical efficacy, achieving an overall objective response rate of 68.5%. Further evaluation indicates that patients under follow-up exceeding six months benefitted even more, with an increased response rate of 89.7%.
These promising findings not only highlight Eratrectinib's therapeutic advantages but also underscore its long-term benefits in patient care. With a remarkable two-year progression-free survival (PFS) rate of 75.7% and a duration of response (DOR) rate of 85.5%, the data strongly supports its role in providing durable disease control and lasting remission for patients. Additionally, the enhanced overall survival (OS) rate, averaging 40.7 months, signifies considerable improvements in long-term patient outcomes.
Both Vcare PharmaTech and Geneseeq are based in the Life Science and Health Industry Office of Nanjing Jiangbei New Area, demonstrating a collaborative history that strengthens their combined efforts toward innovative healthcare solutions. The timing of PanTRKare's approval, just two months after Eratrectinib's marketing authorization in June, establishes a seamless connection in the diagnostic and treatment workflow tailored for NTRK-fusion solid tumors. This progression creates favorable conditions for the identification of patients eligible for Eratrectinib therapy, facilitating early access to effective treatment strategies. The tandem approval of both products not only illustrates the synergistic capabilities fostered through their partnership but also emphasizes the broader industrial strengths found within the Life Science and Health Industry ecosystem located in Nanjing Jiangbei New Area. This ecosystem encourages connections across upstream and downstream industrial chains while cultivating collaborative innovation among firms operating in the area.
For further information regarding commercial cooperation and strategic development, interested parties may reach out to the designated contacts for Vcare PharmaTech and Geneseeq.
In light of these advancements, the approval of PanTRKare™ stands as a pivotal moment in cancer diagnostics, ensuring that patients diagnosed with NTRK fusion-positive tumors are afforded the opportunity to receive targeted therapy promptly. As healthcare continues its relentless pursuit of innovation, the partnership between Vcare PharmaTech and Geneseeq exemplifies the potential that exists when companies unite their resources toward advancing patient care in oncology.
The PanTRKare™ kit effectively addresses several testing challenges within the oncology landscape, specifically the pan-tumor distribution, low incidence rates, and the complex variation patterns of NTRK1/2/3 fusions. By enabling the accurate detection of NTRK fusion variants, this diagnostic tool significantly improves the way healthcare professionals can assess and treat patients with various cancer types.
In clinical settings, the efficacy of PanTRKare™ has been established through validation studies. Results demonstrate that patients with positive test results using PanTRKare™ have shown objective response rates that are in line with those recorded during the clinical trials for Eratrectinib. This consistency has been observed across both treatment-naïve and pre-treated populations, further endorsing the stability and reliability of the assay as a companion diagnostic instrument.
Eratrectinib itself has made waves in the pharmaceutical industry, marking a notable achievement as Nanjing's first innovative drug approval this year. By employing advanced cyclic structural optimization strategies, this next-generation TRK inhibitor exhibits a more potent and highly selective inhibition of TRK kinases. Such innovations effectively address the structural impediments and drug-resistance challenges that hindered the first-generation TRK inhibitors. The pivotal VC004-101 clinical trial showcases Eratrectinib's impressive clinical efficacy, achieving an overall objective response rate of 68.5%. Further evaluation indicates that patients under follow-up exceeding six months benefitted even more, with an increased response rate of 89.7%.
These promising findings not only highlight Eratrectinib's therapeutic advantages but also underscore its long-term benefits in patient care. With a remarkable two-year progression-free survival (PFS) rate of 75.7% and a duration of response (DOR) rate of 85.5%, the data strongly supports its role in providing durable disease control and lasting remission for patients. Additionally, the enhanced overall survival (OS) rate, averaging 40.7 months, signifies considerable improvements in long-term patient outcomes.
Both Vcare PharmaTech and Geneseeq are based in the Life Science and Health Industry Office of Nanjing Jiangbei New Area, demonstrating a collaborative history that strengthens their combined efforts toward innovative healthcare solutions. The timing of PanTRKare's approval, just two months after Eratrectinib's marketing authorization in June, establishes a seamless connection in the diagnostic and treatment workflow tailored for NTRK-fusion solid tumors. This progression creates favorable conditions for the identification of patients eligible for Eratrectinib therapy, facilitating early access to effective treatment strategies. The tandem approval of both products not only illustrates the synergistic capabilities fostered through their partnership but also emphasizes the broader industrial strengths found within the Life Science and Health Industry ecosystem located in Nanjing Jiangbei New Area. This ecosystem encourages connections across upstream and downstream industrial chains while cultivating collaborative innovation among firms operating in the area.
For further information regarding commercial cooperation and strategic development, interested parties may reach out to the designated contacts for Vcare PharmaTech and Geneseeq.
In light of these advancements, the approval of PanTRKare™ stands as a pivotal moment in cancer diagnostics, ensuring that patients diagnosed with NTRK fusion-positive tumors are afforded the opportunity to receive targeted therapy promptly. As healthcare continues its relentless pursuit of innovation, the partnership between Vcare PharmaTech and Geneseeq exemplifies the potential that exists when companies unite their resources toward advancing patient care in oncology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.